Organisation › Details

DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Global Select Market: DBVT)

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). *

	Start	2002-01-01 established
	Industry	Viaskin® allergy treatment
	Industry 2	topical drug delivery technology
	Person	Benhamou, Pierre-Henri (DBV Technologies 201508 CEO + Board Director of Biotech France)
	Person 2	Donne, Nathalie (DBV Technologies 201507 Director CorpComm + Business Development)

	Region	Bagneux, Hauts-de-Seine
	Country	France
	Street	80/84 rue des Meuniers
	City	92220 Bagneux
	Tel	+33-1-5542-7878
		Address record changed: 2018-07-24

Basic data	Employees	D: 101 to 500 (2017-12-31)
	Currency	EUR
	Annual sales	11,909,000 (income, operating, consolidated (2017) 2017-12-31)
	Profit	-147,693,000 (2016-12-31)
	Cash	137,880,000 (2017-12-31)

		* Document for ï¿½About Sectionï¿½: DBV Technologies S.A.. (3/15/17). "Press Release: DBV Technologies Reports Full Year 2016 Financial Results".

		Record changed: 2018-10-30

Top News

Upcoming Events

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Partners

DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Global Select Market: DBVT)

More documents for DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Global Select Market: DBVT)